Lymphoma & Myeloma Clinical Trials | MD Anderson Cancer Center

Lymphoma Clinical Trials

Indolent Lymphoma (Follicular, Marginal Zone, Small Lymphocytic Leukemia)

2024-0385 Randomized Phase III study of mosunetuzumab vs. rituximab for low tumor burden follicular lymphoma

2023-0063 Phase II trial of obinutuzumab and CC-99282 for patients with previously untreated high tumor burden follicular lymphoma

2025-1358 A modular Phase II, single-arm, multicenter, open-label study to evaluate the efficacy and safety of surovatamig (AZD0486) in participants with relapsed or refractory B cell non-Hodgkin lymphoma (SOUNDTRACK-B)

2022-0463 An adaptive Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of axicabtagene ciloleucel versus standard of care therapy as first-line therapy in subjects with high-risk large B cell lymphoma

2022-0394 A Phase lb, open-label, multicenter study evaluating the safety, pharmacokinetics, and efficacy of mosunetuzumab or glofitamab in combination with CC-220 and CC-99282 in patients with B cell non-Hodgkin lymphoma

2022-0551 A Phase I/II, open-label study of valemetostat in combination with rituximab and lenalidomide in relapsed or refractory follicular lymphoma

2022-0459 A Phase II trial of mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide in patients with relapsed B cell NHL

2025-0865 A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma

2025-1078 Pivotal study to validate the usability, safety and diagnostic performance of a novel system to non-invasively detect severe neutropenia

2024-0114 A Phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of epcoritamab + rituximab and lenalidomide (R 2) compared to chemoimmunotherapy in previously untreated follicular lymphoma (EPCORE FL-2)

Aggressive Lymphoma (Large B cell Lymphoma, Diffuse Large B cell Lymphoma, Burkitt's Lymphoma)

2020-1169 A Phase I, dose escalation, safety and tolerability study of NX-2127, a Bruton's tyrosine kinase (BTK) degrader in adults with relapsed/refractory B cell malignancies

2021-1033 An open-label, multi-center, non-randomized Phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T cell lymphoma

2022-0602 An open-label, Phase I study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of RO7227166 (a CD19 targeted 4-1BB ligand) in combination with obinutuzumab and in combination with glofitmab following a pre-treatment dose of obinutuzumab administered in participants with relapsed/refractory B cell non-Hodgkin's lymphoma

2022-0147 A Phase II study of loncastuximab tesirine as consolidation strategy in patients with large B cell lymphoma who achieve partial remission after CAR T cell therapy

2021-1088 A multicenter, open-label feasibility and randomized Phase II study of daratumumab with dose-adjusted EPOCH in newly diagnosed plasmablastic lymphoma with or without HIV

2023-0202 A Phase I multicenter study evaluating the safety and efficacy of ACE1831, an allogeneic CD20-conjugated gamma delta T cell therapy, In adult subjects with relapsed/refractory CD20-expressing B cell malignancies

2024-0243 A Phase II trial of mosunetuzumab and zanubrutinib for patients with relapsed/refractory marginal zone lymphoma

2023-0031 Phase II trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B cell lymphoma

2021-1108 Phase II study of pirtobrutinib with venetoclax in relapsed-refractory MCL (mantle cell lymphoma) patients

2025-0872 An open-label, multicenter, Phase I trial to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma agents, in patients with relapsed or refractory non-Hodgkin lymphomas

2023-0942 A modular Phase I/II, open-label, multicenter study to evaluate the safety, tolerability and efficacy of AZD3470, a PRMT5 inhibitor, as Monotherapy and in combination with Anti-cancer Agents in participants with relapsed/refractory Hematologic Malignancies

2023-0864 A pilot study of emapalumab for the treatment of CAR T cell therapy-associated prolonged cytopenia 2024-0115 A Phase III, randomized, open-label study comparing the efficacy and safety of the combination of Beleodaq-CHOP or Folotyn-COP to the CHOP regimen alone in newly diagnosed patients with peripheral T cell lymphoma 2024-0453 An open-label, dose escalation and dose expansion trial evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered CA-4948 in patients with relapsed or refractory primary central nervous system lymphoma 2024-0430 A Phase I first in human study of ARV-393 in adult participants with advanced non-Hodgkin's lymphoma 2024-1146 A Phase III, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of golcadomide plus R-CHOP chemotherapy vs placebo plus R-CHOP chemotherapy in participants with previously untreated high-risk large B cell lymphoma 2024-1534 A Phase II, open-label, multicenter study of MB-105 in patients with CD5 positive (CD5+) relapsed/refractory T cell lymphoma (r/r TCL) 2024-1549 A modular Phase I/II open-label dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of AZD5492, a T cell-engaging antibody targeting CD20 in subjects with relapsed or refractory B cell malignancies (TITANium) 2025-0344 A Phase II/III, open-label, single-arm, multicenter, historical control study to evaluate ELA026 in participants with secondary hemophagocytic lymphohistiocytosis (sHLH)

2023-0176 A pilot study for pupillary assessment to predict CAR-T related neurotoxicity

2020-0034 A Phase II Study of acalabrutinib, lenalidomide and rituximab (aR2) in patients with previously untreated high tumor burden follicular lymphoma

Mantle Cell Lymphoma

2022-0722 A single-arm, open-label, multicenter Phase II study to evaluate the efficacy, safety, and pharmacokinetics of Bcl-2 inhibitor BGB-11417 in patients with relapsed or refractory mantle cell lymphoma

2023-0695 Tafasitamab, lenalidomide and venetoclax combination therapy for relapsed or refractory Mantle Cell Lymphoma (V-MIND)

2023-0413 Phase II study of pirtobrutinib, rituximab (PR) in previously untreated low and intermediate risk MCL (mantle cell lymphoma) patients

2024-0220 GATE1: A multicenter Phase II study of pirtobrutinib, rituximab and venetoclax combination therapy for patients with previously untreated mantle cell lymphoma

2024-1726 Phase I trial of BTM-3566 in relapsed/refractory mature B cell lymphomas

2025-0045 A Phase III randomized double-blind multicenter study of sonrotoclax plus zanubrutinib versus placebo plus zanubrutinib in patients with relapsed/refractory mantle cell lymphoma

Hodgkin Lymphoma

2021-0091 A multicenter, Phase I, open-label, dose-escalation and expansion study of TNB-486, a bispecific antibody targeting CD19 in subjects with relapsed or refractory B cell non-Hodgkin lymphoma

T Cell Lymphoma

Previously Treated

2023-0962 A Phase III, randomized, open-label study to investigate the efficacy and safety of ITK inhibitor soquelitinib versus physician's choice standard of care treatment (selected single agent) in participants with relapsed/refractory peripheral T cell lymphoma not otherwise specified, follicular helper T cell lymphomas, or systemic anaplastic large-cell lymphoma